• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry

    Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    "It is with great pleasure that we welcome Derrick as the latest addition to our leadership team," said Matt Brokaw, CEO of Aerin Medical. "With a proven track record of financial leadership and a wealth of operating expertise, Derrick will play a pivotal role in accelerating our pursuit of a new standard of care for millions of untreated sufferers of ENT conditions."

    Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation (NASDAQ:LUNG) where he scaled the finance organization and led the company through significant growth and a successful IPO. Before that, he led strategy and corporate development at iRhythm Technologies (NASDAQ:IRTC). Previously, Sung spent seven years on Wall Street as a senior equity research analyst covering the medical devices sector, directed marketing and business development for Boston Scientific's Neuromodulation division, led management consulting engagements at the Boston Consulting Group, and designed heart catheters as an R&D engineer for Guidant Corporation. He received his Ph.D. in bioengineering from the University of California, San Diego, his Master of Business Administration from San Diego State University, and his Bachelor of Science degree in mechanical engineering from Stanford University.

    "I am excited to join the exceptional team at Aerin Medical as we embark on the next phase of growth," said Sung. "Fueled by compelling fundamentals and a rare financial profile, we are poised to achieve remarkable success."

    About Aerin Medical

    Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 100,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231120576987/en/

    Get the next $IRTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC
    $LUNG

    CompanyDatePrice TargetRatingAnalyst
    iRhythm Holdings Inc.
    $IRTC
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    iRhythm Holdings Inc.
    $IRTC
    9/23/2025$185.00In-line
    Evercore ISI
    iRhythm Holdings Inc.
    $IRTC
    8/20/2025$200.00Buy
    BofA Securities
    Pulmonx Corporation
    $LUNG
    7/31/2025$2.50Overweight → Neutral
    Piper Sandler
    iRhythm Holdings Inc.
    $IRTC
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    Pulmonx Corporation
    $LUNG
    3/10/2025$17.00Buy
    D. Boral Capital
    Pulmonx Corporation
    $LUNG
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    iRhythm Holdings Inc.
    $IRTC
    12/3/2024$86.00Equal Weight
    Wells Fargo
    More analyst ratings

    $IRTC
    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded iRhythm from In-line to Outperform and set a new price target of $210.00

    1/5/26 8:34:48 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on iRhythm with a new price target

    BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00

    8/20/25 8:56:18 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iRhythm Holdings Appoints Jason Patten to its Board of Directors

    SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth. "We are thrilled to welcome Jason Patten to our Board of Directors at an important moment in iRhythm's evolution," said Abhi Talwalkar, Chairman of the Board of Directors. "As we scale and expand profitability, we are focus

    3/12/26 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7

    3/4/26 4:06:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Closing of up to $60 Million Credit Facility

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors. The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company's existing debt, and an option to draw an additional $20 million in unfunded capital through the end of 2027, subject to the achievement of certain revenue milestones. The new facility is interest only until maturity in 2031, and bears interest at a rate equal to one-month Term SOFR (subject to

    3/4/26 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

    SCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)

    3/27/26 11:37:40 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Holdings Inc.

    SCHEDULE 13G/A - iRhythm Holdings, Inc. (0001388658) (Subject)

    3/26/26 10:47:20 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by iRhythm Holdings Inc.

    SCHEDULE 13G - iRhythm Holdings, Inc. (0001388658) (Subject)

    3/23/26 4:43:19 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patten Jason H

    4 - iRhythm Holdings, Inc. (0001388658) (Issuer)

    3/19/26 5:39:47 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Patten Jason H

    3 - iRhythm Holdings, Inc. (0001388658) (Issuer)

    3/19/26 5:37:39 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    EVP Strategic Business Ops Smith Mervin sold $295,466 worth of shares (2,585 units at $114.30), decreasing direct ownership by 10% to 23,027 units (SEC Form 4)

    4 - iRhythm Holdings, Inc. (0001388658) (Issuer)

    3/17/26 4:31:36 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Financials

    Live finance-specific insights

    View All

    Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7

    3/4/26 4:06:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatmen

    2/20/26 8:00:00 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $208.9 million, a 27.1% increase compared to fourth quarter 2024Gross margin of 70.9%, a 90-basis point increase compared to fourth quarter 2024Net income of $5.6 million, a $6.9 million improvement compared to fourth quarter 2024 and the first quarter of positive GAAP net income in Company historyAdjusted EBITDA and adjusted EBITDA margin of

    2/19/26 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm Holdings Appoints Jason Patten to its Board of Directors

    SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth. "We are thrilled to welcome Jason Patten to our Board of Directors at an important moment in iRhythm's evolution," said Abhi Talwalkar, Chairman of the Board of Directors. "As we scale and expand profitability, we are focus

    3/12/26 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    4/2/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care